SteelPeak Wealth LLC Grows Position in Bruker Co. (NASDAQ:BRKR)

SteelPeak Wealth LLC increased its position in shares of Bruker Co. (NASDAQ:BRKR) by 16.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,717 shares of the medical research company’s stock after purchasing an additional 1,775 shares during the period. SteelPeak Wealth LLC’s holdings in Bruker were worth $878,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. First Horizon Advisors Inc. boosted its stake in shares of Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after purchasing an additional 218 shares during the period. Covestor Ltd boosted its position in Bruker by 139.1% in the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after buying an additional 210 shares during the period. UMB Bank n.a. boosted its position in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after buying an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd purchased a new stake in Bruker in the 2nd quarter valued at about $52,000. Finally, GAMMA Investing LLC boosted its position in Bruker by 81.0% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after buying an additional 388 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Trading Up 0.8 %

NASDAQ BRKR opened at $58.51 on Thursday. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. The firm has a market cap of $8.50 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.52 and a beta of 1.18. The company has a 50 day moving average price of $64.47 and a 200 day moving average price of $67.30. Bruker Co. has a 52 week low of $55.12 and a 52 week high of $94.86.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $0.52 EPS for the quarter, hitting the consensus estimate of $0.52. The firm had revenue of $800.70 million during the quarter, compared to analyst estimates of $799.44 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. Bruker’s revenue was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.50 EPS. As a group, sell-side analysts forecast that Bruker Co. will post 2.61 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were paid a dividend of $0.05 per share. The ex-dividend date was Friday, August 30th. This represents a $0.20 annualized dividend and a dividend yield of 0.34%. Bruker’s dividend payout ratio (DPR) is presently 7.27%.

Analyst Ratings Changes

Several research firms have issued reports on BRKR. The Goldman Sachs Group lowered their price objective on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Barclays assumed coverage on shares of Bruker in a research report on Tuesday, October 15th. They issued an “overweight” rating and a $75.00 price objective for the company. Wells Fargo & Company assumed coverage on shares of Bruker in a report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 price target for the company. Finally, TD Cowen reduced their price target on shares of Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $80.82.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.